Medications that produce greater reductions in cue-induced alcohol craving appear to be associated with lower rates of return to heavy drinking, but not consistently with other drinking outcomes. This pattern indicates that the cue-reactivity paradigm has limited and outcome-specific translational validity rather than functioning as a universal indicator of clinical efficacy.
Nieto et al. (Sun,) studied this question.